Trial to assess hydroxychloroquine for COVID-19 prevention during cancer treatment – Healio
Nancy Y. Lee, MD, FASTRO

Nancy Y. Lee

A randomized section 2 scientific trial will assess hydroxychloroquine for prevention of COVID-19 an infection amongst sufferers present process radiation remedy for most cancers.

“Sufferers could also be at a better danger for contracting COVID-19 throughout most cancers therapy resulting from elevated publicity,” Nancy Y. Lee, MD, FASTRO, vice chairman and radiation oncologist within the division of radiation oncology at Memorial Sloan Kettering Most cancers Middle, mentioned in a press launch. “There’s an pressing must establish efficient risk-reduction methods for these sufferers who require therapy for his or her most cancers as we await efficient therapeutic choices. This trial will present necessary perception into the potential function that hydroxychloroquine may play in addressing this important want.”

Lee spoke with Healio about what prompted this analysis, the timeline for outcomes and potential implications of the findings.

Question: What’s the rationale for this examine?

Answer: Sufferers who bear each day radiation following a most cancers prognosis have a better danger for COVID-19 an infection resulting from larger publicity charges. Hydroxychloroquine is used for the prevention and therapy of sure kinds of malaria, in addition to rheumatoid arthritis, lupus and porphyria cutanea tarda, and is being evaluated in quite a lot of settings for its potential to stop and deal with COVID-19.

Q: How will you conduct the examine?

A: This section 2, randomized, double-blind, placebo-controlled examine will likely be performed throughout a number of facilities. We are going to enroll sufferers aged 18 years and older who’re present process radiation remedy alone or together with chemotherapy. Individuals will likely be randomly assigned 1:1 to prophylactic hydroxychloroquine or placebo, and we are going to evaluate the chance of symptomatic COVID-19 an infection between the hydroxychloroquine and placebo teams. We may also evaluate the chance of extreme COVID-19 an infection between examine teams and consider acute toxicities related to administration of hydroxychloroquine throughout radiation or chemoradiation.

Q: What do you anticipate to discover?

A: We hypothesize that hydroxychloroquine will lower the chance for COVID-19 an infection by half, as there are preclinical information that present this rationale to be sound and that hydroxychloroquine can lower danger.

Q: When do you anticipate completion of the examine and when may information be obtainable?

A: Completion of the examine relies upon upon affected person enrollment, however we hope to finish the trial throughout the subsequent three to six months and have a knowledge readout shortly thereafter.

Q: What will the influence be, if confirmed efficient?

A: The potential influence is that sufferers can take hydroxychloroquine and anticipate a decrease danger for COVID-19 an infection throughout radiation therapy for most cancers. That is necessary, as sufferers who’re optimistic for COVID-19 and are present process most cancers remedy don’t do in addition to these with out COVID-19.

Q: Is there anything that you simply wish to point out?

A: We’re excited to conduct this examine as a result of it is sensible mechanistically. If we wait till sufferers are very sick with COVID-19 an infection, hydroxychloroquine could have no impact, which is what we see within the present printed trials. – by Jennifer Southall

For extra info:

Nancy Y. Lee, MD, FASTRO, could be reached at Memorial Sloan Kettering Most cancers Middle, 633 Third Ave., 2nd Ground, New York, NY 10017; e mail: leen2@mskcc.org.

Disclosure: Lee studies no related monetary disclosures.

Nancy Y. Lee, MD, FASTRO

Nancy Y. Lee

A randomized section 2 scientific trial will assess hydroxychloroquine for prevention of COVID-19 an infection amongst sufferers present process radiation remedy for most cancers.

“Sufferers could also be at a better danger for contracting COVID-19 throughout most cancers therapy resulting from elevated publicity,” Nancy Y. Lee, MD, FASTRO, vice chairman and radiation oncologist within the division of radiation oncology at Memorial Sloan Kettering Most cancers Middle, mentioned in a press launch. “There’s an pressing must establish efficient risk-reduction methods for these sufferers who require therapy for his or her most cancers as we await efficient therapeutic choices. This trial will present necessary perception into the potential function that hydroxychloroquine may play in addressing this important want.”

Lee spoke with Healio about what prompted this analysis, the timeline for outcomes and potential implications of the findings.

Question: What’s the rationale for this examine?

Answer: Sufferers who bear each day radiation following a most cancers prognosis have a better danger for COVID-19 an infection resulting from larger publicity charges. Hydroxychloroquine is used for the prevention and therapy of sure kinds of malaria, in addition to rheumatoid arthritis, lupus and porphyria cutanea tarda, and is being evaluated in quite a lot of settings for its potential to stop and deal with COVID-19.

Q: How will you conduct the examine?

A: This section 2, randomized, double-blind, placebo-controlled examine will likely be performed throughout a number of facilities. We are going to enroll sufferers aged 18 years and older who’re present process radiation remedy alone or together with chemotherapy. Individuals will likely be randomly assigned 1:1 to prophylactic hydroxychloroquine or placebo, and we are going to evaluate the chance of symptomatic COVID-19 an infection between the hydroxychloroquine and placebo teams. We may also evaluate the chance of extreme COVID-19 an infection between examine teams and consider acute toxicities related to administration of hydroxychloroquine throughout radiation or chemoradiation.

Q: What do you anticipate to discover?

A: We hypothesize that hydroxychloroquine will lower the chance for COVID-19 an infection by half, as there are preclinical information that present this rationale to be sound and that hydroxychloroquine can lower danger.

Q: When do you anticipate completion of the examine and when may information be obtainable?

A: Completion of the examine relies upon upon affected person enrollment, however we hope to finish the trial throughout the subsequent three to six months and have a knowledge readout shortly thereafter.

Q: What will the influence be, if confirmed efficient?

PAGE BREAK

A: The potential influence is that sufferers can take hydroxychloroquine and anticipate a decrease danger for COVID-19 an infection throughout radiation therapy for most cancers. That is necessary, as sufferers who’re optimistic for COVID-19 and are present process most cancers remedy don’t do in addition to these with out COVID-19.

Q: Is there anything that you simply wish to point out?

A: We’re excited to conduct this examine as a result of it is sensible mechanistically. If we wait till sufferers are very sick with COVID-19 an infection, hydroxychloroquine could have no impact, which is what we see within the present printed trials. – by Jennifer Southall

For extra info:

Nancy Y. Lee, MD, FASTRO, could be reached at Memorial Sloan Kettering Most cancers Middle, 633 Third Ave., 2nd Ground, New York, NY 10017; e mail: leen2@mskcc.org.

Disclosure: Lee studies no related monetary disclosures.

News Reporter

Leave a Reply

Your email address will not be published. Required fields are marked *

X